The Group has three reportable segments, as discussed below, which are based on information provided to the Board of Directors, which is deemed to be the Group's chief operating decision maker. Several operating segments which have similar economic characteristics have been aggregated into the reporting segments. In undertaking this aggregation the assessment determined that the aggregated segments have similar products, production processes, customers and overall regulatory environment.

The European Pharmaceuticals Segment comprises Dechra Veterinary Products EU, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. This Segment operates internationally and manufactures and markets Companion Animal, Equine, Food producing Animal Products and Nutrition. This Segment also includes third party manufacturing and other non-core activities sales. The Segment expanded during the year with the acquisition of RxVet Limited, AST Farma B.V. and Le Vet Beheer B.V.

The North American Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel, which sells Companion Animal, Equine Products and Food producing Animal Products in those territories. The Segment also includes our manufacturing unit based in Melbourne, Florida.

The Pharmaceuticals Research and Development Segment includes all of the Group's pharmaceutical research and development activities. From a Board perspective, this Segment has no revenue income.

Reconciliation of reportable segment revenues, profit or loss and liabilities and other material items:

2018
£m
2017
£m
Revenue by segment
European Pharmaceuticals — total258.7226.9
NA Pharmaceuticals    — total148.4132.4
407.1359.3
Operating profit/(loss) by segment
European Pharmaceuticals77.060.7
NA Pharmaceuticals48.343.2
Pharmaceuticals Research and Development(18.3)(15.0)
Segment operating profit107.088.9
Corporate and other unallocated costs(7.8)(7.6)
Underlying operating profit99.281.3
Amortisation of acquired intangibles(54.1)(40.4)
Remeasurement of contingent consideration0.1
Impairment of assets available for sale(0.6)
Fair value uplift of inventory acquired through business combinations(5.1)(4.2)
Rationalisation costs on business acquisitions(0.8)
Rationalisation of manufacturing organisation(2.9)
Expenses relating to acquisition activities(3.1)(2.1)
Total operating profit34.133.2
Finance income1.50.8
Finance expense(6.4)(5.3)
Share of losses in investment accounted for using the equity method(0.3)(0.1)
Profit before taxation28.928.6
Total liabilities by segment
European Pharmaceuticals(79.6)(73.7)
NA Pharmaceuticals(31.0)(20.2)
Pharmaceuticals Research and Development(1.4)(0.4)
Segment liabilities(112.0)(94.3)
Corporate loans and revolving credit facility(291.1)(181.2)
Corporate accruals and other payables(6.5)(8.2)
Current and deferred tax liabilities(102.7)(51.8)
(512.3)(335.5)
Revenue by product category
CAP266.7223.8
Equine34.427.2
FAP48.747.3
Nutrition29.427.5
Other27.933.5
407.1359.3
Additions to intangible non-current assets by segment (including through business combinations)
European Pharmaceuticals370.264.5
NA Pharmaceuticals6.94.4
Pharmaceuticals Research and Development0.41.4
Corporate and central costs0.50.1
378.070.4
Additions to Property, Plant and Equipment by segment (including through business combinations)
European Pharmaceuticals4.910.1
NA Pharmaceuticals0.20.5
Pharmaceuticals Research and Development0.20.1
Corporate and central costs0.2
5.510.7
Depreciation and amortisation by segment
European Pharmaceuticals40.922.7
NA Pharmaceuticals18.623.4
Pharmaceuticals Research and Development0.50.5
Corporate and central costs1.50.7
61.547.3
The total depreciation, amortisation and impairment charge is made up of the following:
Non-underlying
Amortisation — selling, general and administrative expenses46.129.0
Amortisation — research and development expenditure8.011.4
54.140.4
Underlying
Amortisation and impairment2.62.0
Depreciation4.84.9
7.46.9

Geographical Information

The following table shows revenue based on the geographical location of customers and non-current assets based on the country of domicile of the entity holding the asset:

2018
Revenue
£m
2018
Non-
current
assets
£m
2017
Revenue
£m
2017
Non-
current
assets
£m
UK56.118.956.315.6
Germany40.42.437.42.4
Rest of Europe138.3493.9113.1192.4
USA139.8180.1124.1193.2
Rest of World32.574.128.449.5
407.1769.4359.3453.1